| Name | Title | Contact Details |
|---|
Confluent Medical Technologies is the leading contract manufacturer of Nitinol-based components, balloon components, and balloon catheters.
Enclara Pharmacia is the combination resulting from the August 2014 acquisition of Hospice Pharmacia by Enclara Health. We believe that this marriage creates the only true solution for hospice mail order pharmacy services and augments an already robust PBM local offering for hospices that want a choice in their pharmacy service model. Andy Horowitz, CEO, continues to lead Enclara Pharmacia. Enclara Pharmacia serves over 500 hospice providers and 84,000 hospice patients per day nationwide. Enclara’s mail order model provides comprehensive pharmacy support, delivering medications directly to hospice patients’ homes, with the backup of local pharmacies to serve their same-day and emergency needs. Comprehensive services include pharmacist consultation 24/7, patient Drug Utilization Review (DUR), Conditions of Participation (CoP) reports, formulary management, account management, and online reporting—all bundled into a predictable per diem reimbursement model. Enclara Pharmacia’s PBM Plus offering provides you with abundant choice and access to our powerful local pharmacy network contracting platform. The service is offered at a fee for service (FFS) price, unbundled, allowing you to choose the level of clinical intervention, if any, your hospice requires, and to “pay as you go” as those resources are utilized. The program gives the control back to you, supporting overall cost containment.
Nasco Healthcare simulation for healthcare training solutions ensures frontline heroes are READY in any situation. 5-year warranty and 100% made in the US.
Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn`s disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction.
Valeant Pharmaceuticals International, Inc. is a diverse and decentralized pharmaceutical company that is committed to focusing on our key stakeholders while delivering consistently high performance. Our values provide the overall direction for our company, and provide us with the tools necessary to rise to any challenge by leveraging our collective hard work and effort along with our unwavering competitive spirit. These values help us set goals based on our organization’s potential and what we hope it will become.